eligibility_summary
Adults (≥18) with ECOG 0–1 and CLDN6+ metastatic/unresectable solid tumors (e.g., NSCLC, EOC, TNBC, germ cell, endometrial), post–standard therapy. CLDN6 testing per cohort, measurable lesion required for expansion. Life expectancy >3 months, adequate organ function. Excludes HIV/HBV/HCV+, recent other cancer (<2y), active infection, unstable/untreated CNS mets, recent investigational/anticancer therapy or major surgery, steroid‑dependent autoimmunity, pregnancy/lactation or inadequate contraception, hypersensitivity, or poor compliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drug/intervention: AMG 794, an investigational immunotherapy administered by short IV infusion (Phase 1, first-in-human). Mechanism: Not specified in the registry, described as an anti–Claudin-6 (CLDN6)–targeted therapy intended to exert anti-tumor activity against CLDN6-expressing cancers. Cells/pathways targeted: Tumor cells expressing CLDN6, a claudin family tight-junction protein aberrantly present on certain solid tumors (e.g., non-squamous NSCLC, epithelial ovarian cancer, and other CLDN6+ malignancies). Status: Trial terminated due to sponsor strategic decision.